Related Experiment Video
Updated: Jul 25, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Regulation of PD-L1 Expression by Nuclear Receptors
Yoshimitsu Kiriyama1,2, Hiromi Nochi1
1Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima 769-2193, Kagawa, Japan.
Abstract:
The suppression of excessive immune responses is necessary to prevent injury to the body, but it also allows cancer cells to escape immune responses and proliferate. Programmed cell death 1 (PD-1) is a co-inhibitory molecule that is present on T cells and is the receptor for programmed cell death ligand 1 (PD-L1). The binding of PD-1 to PD-L1 leads to the inhibition of the T cell receptor signaling cascade. PD-L1 has been found to be expressed in many types of cancers, such as lung, ovarian, and breast cancer, as well as glioblastoma. Furthermore, PD-L1 mRNA is widely expressed in normal peripheral tissues including the heart, skeletal muscle, placenta, lungs, thymus, spleen, kidney, and liver. The expression of PD-L1 is upregulated by proinflammatory cytokines and growth factors via a number of transcription factors. In addition, various nuclear receptors, such as androgen receptor, estrogen receptor, peroxisome-proliferator-activated receptor γ, and retinoic-acid-related orphan receptor γ, also regulate the expression of PD-L1. This review will focus on the current knowledge of the regulation of PD-L1 expression by nuclear receptors.
Insights
Nuclear receptors regulate programmed cell death ligand 1 (PD-L1) expression, impacting cancer immune evasion. Understanding this regulation is key to developing new cancer immunotherapies.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Immune suppression prevents self-injury but aids cancer growth.
- Programmed cell death 1 (PD-1) and its ligand PD-L1 inhibit T cell responses.
- PD-L1 is expressed in various cancers and normal tissues, promoting immune escape.
Purpose of the Study:
- To review the regulation of PD-L1 expression.
- To focus on the role of nuclear receptors in PD-L1 regulation.
Main Methods:
- Literature review of PD-L1 expression and regulation.
- Analysis of PD-L1 upregulation by cytokines and transcription factors.
- Examination of nuclear receptor control over PD-L1.
Main Results:
- PD-L1 expression is upregulated by inflammatory signals.
- Nuclear receptors including androgen receptor, estrogen receptor, PPARγ, and RORγ regulate PD-L1.
- PD-L1 is expressed in multiple cancer types and normal tissues.
Conclusions:
- Nuclear receptors play a significant role in controlling PD-L1 expression.
- Targeting nuclear receptor regulation of PD-L1 may offer novel cancer therapy strategies.
Related Concept Videos
Regulation of Nuclear Protein Sorting
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Regulation of the Unfolded Protein Response
Negative Regulator Molecules
Regulation of Expression at Multiple Steps

